ITF

ANTI-DOPING T he ITF continued in its role as operator of the Tennis Anti-Doping Programme which applies to all players who have a WTA/ATP ranking, or who enter or compete in a covered event. Covered events include Davis Cup by BNP Paribas and Fed Cup by BNP Paribas, Grand Slam tournaments and ATP and WTAsanctioned events. The Tennis Anti-Doping Programme remains fully compliant with the WADA Code. In 2012, testing was conducted on five continents under the Tennis Anti-Doping Programme, and comprised over 2,180 samples at 64 events. Both urine and blood samples were collected during in-competition and out-of-competition periods and all were taken with no advance notice to the athlete. A fully WADA-compliant year-round out-of-competition whereabouts testing programme was again implemented in 2012. The ITF's International Registered Testing Pool (IRTP) included the Top 50 men and women, Top 10 men's and women's doubles players, and the Top five wheelchair men, women and quad players. Over 330 'no advance notice' out-of-competition missions were conducted during 2012. From the samples collected under the Tennis Anti-Doping Programme in 2012, two Anti-Doping Rule Violations had been reported at the time of writing, both of which were published on the ITF Tennis Anti-Doping Programme website, www.ITFtennis.com/anti-doping, in accordance with the requirements of the WADA Code. In addition to the above decisions, the ITF announced that it recognises and respects the lifetime ban imposed on Dr Luis Garcia del Moral by the United States Anti-Doping Agency (USADA) for various Anti-Doping Rule Violations. Dr Garcia del Moral was banned by USADA for possession, trafficking and administration of prohibited substances, and assisting, encouraging, aiding, abetting, covering up and other complicity involving one or more anti-doping rule violations and/or attempted anti-doping rule violations. A number of education materials provided by the Tennis Anti-Doping Programme were developed and/or re-designed in 2012. These, in combination with the deterrence and detection aspects of the testing programme, make an important contribution to an effective anti-doping programme. Over 2180 drug tests were conducted at 64 events under the 2012 Tennis Anti-Doping Programme 2012 ITF Testing Summary In-competition testing (urine) Total Male Female Specimens SpecimensSpecimens ITF 1,727 Total 1,727 977750 In-competition testing (blood) 977 750 Total Male Female Specimens SpecimensSpecimens ITF 124 8143 Total 124 8143 Out-of-competition testing (urine) Total Male Female Specimens SpecimensSpecimens ITF/WADA 271 Total 271 143128 Out-of-competition testing (blood) 143 128 Total Male Female Specimens SpecimensSpecimens ITF / WADA 63 Total 63 3429 34 29 Total Testing Summary (in- and out-of-competition, Total MaleFemale for urine and blood)SpecimensSpecimensSpecimens Total 2,1851,235 950 Note: Figures do not include samples collected by National Anti-Doping Organisations or at the 2012 London Olympic and Paralympic Games. 28 SCIENCE & TECHNICAL

• Cover